keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/29146306/real-world-vision-in-age-related-macular-degeneration-patients-treated-with-single-anti-vegf-drug-type-for-1-year-in-the-iris-registry
#1
Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W Parke, George A Williams
PURPOSE: The purpose of this study is to compare real-world visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single anti-vascular endothelial growth factor (VEGF) drug monotherapy for 1 year from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight (IRIS) Registry. DESIGN: Retrospective, nonrandomized, comparative study. PARTICIPANTS: IRIS Registry patients with nAMD who received bevacizumab, ranibizumab, or aflibercept only for 1 year between 2013-2016...
November 13, 2017: Ophthalmology
https://www.readbyqxmd.com/read/29137019/optical-coherence-tomography-angiography-in-patients-with-diabetic-retinopathy-treated-with-anti-vegf-intravitreal-injections-case-report
#2
Katarzyna Michalska-Małecka, Anna Heinke Knudsen
PURPOSE: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR. METHODS: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Patients were injected intravitreally a loading phase of 3 monthly 2.0 mg aflibercept, followed by 2 injections bimonthly (5 injections in total)...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#3
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29131696/risk-factors-for-discontinuation-of-treatment-for-neovascular-age-related-macular-degeneration
#4
Inger Westborg, Aldana Rosso
PURPOSE: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD). METHODS: Data from the Swedish Macula Register and the Skåne Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14 months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree...
November 13, 2017: Ophthalmic Epidemiology
https://www.readbyqxmd.com/read/29130626/age-related-macular-degeneration-using-morphological-predictors-to-modify-current-treatment-protocols
#5
REVIEW
Mohammed Ashraf, Ahmed Souka, Ron A Adelman
To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt to develop a patient-centric treatment algorithm. We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic indicators/predictive factors with the key words: 'age related macular degeneration', 'neovascular AMD', 'choroidal neovascular membrane (CNV)', 'anti-vascular endothelial growth factor (anti-VEGF)', 'aflibercept', 'ranibizumab', 'bevacizumab', 'randomized clinical trials', 'post-hoc', 'prognostic', 'predictive', 'response' 'injection frequency, 'treat and extend (TAE), 'pro re nata (PRN)', 'bi-monthly' and 'quarterly'...
November 11, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29127751/-the-benefit-of-new-angiogenesis-bevacizumab-and-aflibercept-inhibitors-for-multiple-angiomatosis-therapy-a%C3%A2-case-report
#6
Dagmar Brančíková, Lenka Ostřížková, Zdeněk Adam, Tomáš Nebeský, Luděk Pour, Zdeněk Král, Jiří Mayer
Angiomatosis is a term for multiple, gradually proliferating hemangiomas (angiodysplasia), affecting multiple organs or tissues at the same time. We describe a 12-year course of treatment of a patient with multiple hemangiomas located in the abdomen, retroperitoneum, oesophagus, mediastinum and also in vertebrae. The diagnosis was made in 2005 within probatory laparotomy, at the age of 28 years. The treatment was commenced right after making the diagnosis with interferon α. Due to its adverse effects (fatigue, anorexia), the use of interferon α was limited to the first year, after which the interferon dose was gradually being reduced until it was discontinued completely...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29127134/radiation-retinopathy-treated-successfully-with-aflibercept
#7
Pakinee Pooprasert, Tafadzwa Young-Zvandasara, Ayad Al-Bermani
Aflibercept (aflibercept) is a novel anti-vascular endothelial growth factor drug indicated for wet age-related macular degeneration and macular oedema secondary to retinal vein occlusion and diabetic macular oedema. While only newly introduced on the market, it is growing in popularity and over 5.5 million doses have been prescribed worldwide. Due to its versatile mechanism, it is indicated for numerous eye pathologies, and in particular, has been adapted to treat various types of retinopathy. To our knowledge, this is the first case report of solely using aflibercept to treat cystoid macular oedema in radiation retinopathy...
November 9, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29113742/change-in-choroidal-thickness-after-intravitreal-injection-for-treatment-of-neovascular-age-related-macular-degeneration-ranibizumab-versus-aflibercept
#8
F Kaya
PURPOSE: To compare the changes in subfoveal choroidal thickness after intravitreal ranibizumab or aflibercept injections for neovascular age-related macular degeneration (nAMD). METHODS: In this retrospective study, 28 eyes with nAMD treated with 3 consecutive monthly injections of ranibizumab (IVR) and 24 eyes with nAMD treated with 3 consecutive monthly injections of aflibercept (IVA) between September 2012 and June 2016 were reviewed. The follow-up time was 6 months...
November 4, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/29108393/anti-vascular-endothelial-growth-factor-for-unilateral-acute-idiopathic-maculopathy
#9
Georgios Mylonas, Franz Prager, Barbara Wetzel, Panagiotis Malamos, Gabor Deak, Michael Amon
PURPOSE: To describe a case of unilateral acute idiopathic maculopathy (UAIM) response to intravitreal therapy with aflibercept (Eylea). METHODS: Retrospective case report. RESULTS: A 36-year-old woman with sudden visual impairment and central scotoma was found to have a UAIM in her left eye. Three weeks after continuous worsening of her visual acuity and central scotoma, the patient was treated with intravitreal injections of aflibercept...
October 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29108104/renal-function-after-intravitreal-administration-of-vascular-endothelial-growth-factor-inhibitors-in-patients-with-diabetes-and-chronic-kidney-disease
#10
Yusuke Kameda, Tetsuya Babazono, Yasuko Uchigata, Shigehiko Kitano
This study aimed to determine whether intravitreal administration of vascular endothelial growth factor inhibitors is associated with deterioration of renal function, as seen with systemic administration, in patients with diabetes and chronic kidney disease. Estimated glomerular filtration rates before and after 160 intravitreal injections of vascular endothelial growth factor inhibitors (aflibercept, bevacizumab, or ranibizumab) were compared in 69 patients with diabetes and with a baseline estimated glomerular filtration rate <60 mL/min/1...
November 6, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29103187/real-world-treatment-patterns-and-effectiveness-among-patients-with-metastatic-colorectal-cancer-treated-with-ziv-aflibercept-in-community-oncology-practices-in-the-usa
#11
Jasmina I Ivanova, Kimberly R Saverno, Jennifer Sung, Mei Sheng Duh, Chen Zhao, Sean Cai, Francis Vekeman, Aaron Peevyhouse, Ravinder Dhawan, Charles S Fuchs
Routine clinical practice data often differ from clinical trials. This study describes real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) receiving ziv-aflibercept in non-academic, community oncology practices in the USA. De-identified electronic medical records from Vector Oncology and Altos Solutions databases were analysed. We identified 218 patients diagnosed with mCRC who had received prior oxaliplatin therapy and initiated ziv-aflibercept as part of second-line or later-line therapy...
November 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29095879/advanced-quantitative-analysis-of-the-sub-retinal-pigment-epithelial-space-in-recurrent-neovascular-age-related-macular-degeneration
#12
Mariko Sasaki, Yu Kato, Kaoru Fujinami, Toshiaki Hirakata, Kazushige Tsunoda, Ken Watanabe, Kunihiko Akiyama, Toru Noda
To quantitatively evaluate changes in the sub-retinal pigment epithelial (RPE) space and determine the association with recurrent neovascular age-related macular degeneration (AMD). Twenty-two eyes treated with intravitreal aflibercept for treatment-naïve neovascular AMD were studied retrospectively. The sub-RPE area, volume, and central retinal thickness (CRT) were evaluated 1 and 2 months after the loading phase using spectral-domain optical coherence tomography. Recurrence was defined as newly detected neovascular activity during the 6 months after the loading phase...
2017: PloS One
https://www.readbyqxmd.com/read/29094168/systemic-biodistribution-and-intravitreal-pharmacokinetic-properties-of-bevacizumab-ranibizumab-and-aflibercept-in-a-nonhuman-primate-model
#13
John Byron Christoforidis, Karen Briley, Katherine Binzel, Prayna Bhatia, Lai Wei, Krishan Kumar, Michael Vinzenz Knopp
Purpose: To determine the intravitreal pharmacokinetic properties and to study the systemic biodistribution characteristics of I-124-labeled bevacizumab, ranibizumab, and aflibercept with positron emission tomography-computed tomography (PET/CT) imaging in a nonhuman primate model. Methods: Three groups with four owl monkeys per group underwent intravitreal injection with 1.25 mg/0.05 mL I-124 bevacizumab, 0.5 mg/0.05 mL I-124 ranibizumab, or 2.0 mg/0.05 mL I-124 aflibercept in the right eye of each subject...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29094167/effects-of-aflibercept-for-neovascular-age-related-macular-degeneration-a-systematic-review-and-meta-analysis-of-observational-comparative-studies
#14
Yan Zhang, Catherine Chioreso, Marin L Schweizer, Michael D Abràmoff
Purposes: To compare the effects of aflibercept and other anti-vascular endothelial growth factor (anti-VEGF) medications on both functional and anatomical outcomes for treatment-naïve neovascular age-related macular degeneration (nAMD) in the real world. Methods: A systematic review and meta-analysis of observational comparative studies. Results: A total of 18 studies remained after literature selection and quality assessment of 1697 studies...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29093970/two-year-outcome-of-aflibercept-in-patients-with-pigment-epithelial-detachment-due-to-neovascular-age-related-macular-degeneration-namd-refractory-to-ranibizumab
#15
Thi Ha Chau Tran, Stéphane Dumas, Florence Coscas
Purpose: To evaluate the response of intravitreal aflibercept injection (IAI) in eyes with detachment of retinal pigment epithelium (DEP) secondary to nAMD refractory to monthly ranibizumab. Patients and Methods: This is a retrospective, multicenter study. All patients received 3 IAI then treated as needed every 4 weeks for 12 months. During the second year, the eyes were treated with a treat- and-extend regimen. Results: Forty-four eyes were included...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29082448/aflibercept-in-diabetic-macular-edema-refractory-to-previous-bevacizumab-outcomes-and-predictors-of-success
#16
Rita Laiginhas, Marta Inês Silva, Vitor Rosas, Susana Penas, Vitor Adriano Fernandes, Amândio Rocha-Sousa, Ângela Carneiro, Fernando Falcão-Reis, Manuel Sousa Falcão
PURPOSE: To evaluate functional and anatomical outcomes after aflibercept in patients with diabetic macular edema (DME) with poor response to bevacizumab. METHODS: We retrospectively reviewed patients with DME recalcitrant to bevacizumab who were switched to aflibercept between January and December 2015. All patients had a minimal follow-up of three months before the conversion and underwent at least three injections of bevacizumab. Functional outcome consisted in best corrected visual acuity (VA)...
October 29, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29077188/aflibercept-in-the-treatment-of-diabetic-macular-edema-a-review-and-consensus-paper
#17
Teresio Avitabile, Claudio Azzolini, Francesco Bandello, Francesco Boscia, Sandro De Falco, Diego Fornasari, Paolo Lanzetta, Leonardo Mastropasqua, Edoardo Midena, Federico Ricci, Giovanni Staurenghi, Monica Varano
PURPOSE: To reach a consensus, among experts, on the role of aflibercept in diabetic macular edema (DME) through literature review. METHODS: Two round tables, involving 12 Italian experts, were organized: in the first one, 6 pharmacologic and clinical questions were selected and analyzed by a systematic literature review, using a population, intervention, control, and outcomes framework; in the second one, the nominal group technique was used to discuss relevant evidence related to each question...
October 14, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29074161/score2-report-5-vision-related-function-in-patients-with-macular-edema-secondary-to-central-retinal-or-hemiretinal-vein-occlusion
#18
Ingrid U Scott, Maria J Figueroa, Neal L Oden, Michael S Ip, Barbara A Blodi, Paul C VanVeldhuisen
PURPOSE: To describe baseline vision-related function, measured with the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), in patients with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline relationship between NEI VFQ-25 scores with visual acuity letter score (VALS) and central retinal thickness; and compare baseline NEI VFQ-25 scores in SCORE2 participants with those in normal-vision reference populations and patients in other retinal vein occlusion trials...
October 23, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29073892/multiple-criteria-decision-analysis-in-the-context-of-health-technology-assessment-a-simulation-exercise-on-metastatic-colorectal-cancer-with-multiple-stakeholders-in-the-english-setting
#19
Aris Angelis, Gilberto Montibeller, Daniel Hochhauser, Panos Kanavos
BACKGROUND: Multiple criteria decision analysis (MCDA) has appeared as a methodology to address limitations of economic evaluation in health technology assessment (HTA), however there are limited empirical evidence from real world applications. The aim of this study is to test in practice a recently developed MCDA methodological framework known as Advance Value Framework (AVF) through a proof-of-concept case study engaging multiple stakeholders. METHODS: A multi-attribute value theory methodological process was adopted involving problem structuring, model building, model assessment and model appraisal phases...
October 26, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/29061629/a-longitudinal-study-to-assess-the-frequency-and-cost-of-antivascular-endothelial-therapy-and-inequalities-in-access-in-england-between-2005-and-2015
#20
William Hollingworth, Tim Jones, Barnaby C Reeves, Tunde Peto
OBJECTIVES: High-cost antivascular endothelial growth factor (anti-VEGF) medicines for eye disorders challenge ophthalmologists and policymakers to provide fair access for patients while minimising costs. We describe the growth in the use and costs of these medicines and measure inequalities in access. DESIGN: Longitudinal study using Hospital Episode Statistics (2005/2006 to 2014/2015) and hospital prescribing cost reports (2008/2009 to 2015/2016). We used Poisson regression to estimate standardised rates and explore temporal and geographical variations...
October 22, 2017: BMJ Open
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"